-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $8

Benzinga·05/13/2025 14:05:18
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $7 to $8.